BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...who will retire from the trade group at year end. Amphivena Therapeutics Inc. said Curtis Ruegg...
...CEO. Guenot, who is a founder of the immuno-oncology company, will remain as an adviser. Ruegg...
BioCentury | May 16, 2019
Company News

Genentech adds to autoimmune pipeline with Parvus deal

...to develop and commercialize Navacims to treat Type I diabetes. Parvus President and CEO Curtis Ruegg...
BioCentury | May 30, 2018
Company News

Management tracks: Zafgen, Rigel

...BioTherapeutics Inc. (NASDAQ:AGLE). Nanomedicine company Parvus Therapeutics Inc. (Burlingame, Calif.) said Chief Development Officer Curtis Ruegg...
Items per page:
1 - 3 of 3
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...who will retire from the trade group at year end. Amphivena Therapeutics Inc. said Curtis Ruegg...
...CEO. Guenot, who is a founder of the immuno-oncology company, will remain as an adviser. Ruegg...
BioCentury | May 16, 2019
Company News

Genentech adds to autoimmune pipeline with Parvus deal

...to develop and commercialize Navacims to treat Type I diabetes. Parvus President and CEO Curtis Ruegg...
BioCentury | May 30, 2018
Company News

Management tracks: Zafgen, Rigel

...BioTherapeutics Inc. (NASDAQ:AGLE). Nanomedicine company Parvus Therapeutics Inc. (Burlingame, Calif.) said Chief Development Officer Curtis Ruegg...
Items per page:
1 - 3 of 3